Entera Bio (ENTX) 10-Q2024 Q3 Quarterly report

Filed: 8 Nov 24, 4:08pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: abducted, aggression, air, ballistic, budget, Center, Cont, customer, densely, displacement, downgraded, exemption, exerting, exposure, extremist, geopolitical, glucose, ground, guided, heightened, hostage, iii, input, inventive, Iraq, Israeland, labor, lapsed, lethal, lieu, Moody, multiple, North, northern, onset, pig, Red, rendered, rodent, Sea, shareholder, shipping, showed, somemilitary, South, systemic, terror, topline, unique, Yemen, young

Removed: existence, explanatory, expressing, independent, NDA, paragraph

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

ENTX similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES OXLEY ACT OF 2002

I, Miranda Toledano, Chief Executive Officer of Entera Bio Ltd. (the “Company”), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350 that, to the best of my knowledge:

the Quarterly Report on Form 10-Q of the Company for the fiscal quarter ended September 30, 2024 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and

the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 8, 2024

/s/ Miranda Toledano

Miranda Toledano

Chief Executive Officer

(Principal Executive Officer)

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.